Blockchain Registration Transaction Record

Viromed Secures Major Funding for Revolutionary Cold Plasma Medical Tech

Viromed Medical AG receives high six-figure funding from German Federal Ministry for cold plasma technology development, including PulmoPlas® for respiratory infections and ViroCap® for wound healing.

This development matters because it accelerates the availability of potentially transformative medical technologies that could significantly improve patient outcomes in critical care settings. Cold plasma technology represents a non-pharmacological approach to infection control, addressing the growing global challenge of antimicrobial resistance and hospital-acquired infections. The PulmoPlas® system specifically targets respiratory infections, which remain a leading cause of mortality in intensive care units worldwide. By providing alternative treatment modalities that don't rely on traditional antibiotics, these innovations could help combat drug-resistant pathogens while reducing healthcare costs associated with prolonged hospital stays and complex infection management. For patients, this means potentially faster recovery times, reduced risk of complications, and access to more effective treatments for serious infections.